Canada markets open in 8 hours 24 minutes
  • S&P/TSX

    20,595.89
    +4.89 (+0.02%)
     
  • S&P 500

    4,349.93
    -6.52 (-0.15%)
     
  • DOW

    34,168.09
    -129.61 (-0.38%)
     
  • CAD/USD

    0.7866
    -0.0030 (-0.38%)
     
  • CRUDE OIL

    86.63
    -0.72 (-0.82%)
     
  • BTC-CAD

    45,754.03
    -2,382.49 (-4.95%)
     
  • CMC Crypto 200

    819.34
    -36.47 (-4.26%)
     
  • GOLD FUTURES

    1,811.90
    -17.80 (-0.97%)
     
  • RUSSELL 2000

    1,976.46
    -27.57 (-1.38%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • NASDAQ futures

    13,928.75
    -229.75 (-1.62%)
     
  • VOLATILITY

    31.96
    +0.80 (+2.57%)
     
  • FTSE

    7,469.78
    +98.32 (+1.33%)
     
  • NIKKEI 225

    26,189.82
    -821.51 (-3.04%)
     
  • CAD/EUR

    0.7010
    -0.0010 (-0.14%)
     

EU says Pfizer/BioNTech to deliver 75 million extra vaccine doses in second quarter

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • PFE
  • BNTX

By Kate Abnett

BRUSSELS, Feb 1 (Reuters) - Pfizer and German partner BioNTech will deliver 75 million extra doses of their COVID-19 vaccine in the second quarter of the year, European Commission President Ursula von der Leyen said on Monday.

"BioNTech/Pfizer will deliver 75 million of additional doses in the second quarter of the year - and up to 600 millions in total in 2021," von der Leyen wrote on Twitter.

The EU, whose member states are far behind Israel, Britain and the United States in rolling out vaccines, is scrambling to get supplies just as the West’s biggest drugmakers slow deliveries to the bloc due to production problems. (Reporting by Kate Abnett, editing by Marine Strauss)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting